JP2024518426A5 - - Google Patents

Info

Publication number
JP2024518426A5
JP2024518426A5 JP2023568475A JP2023568475A JP2024518426A5 JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5 JP 2023568475 A JP2023568475 A JP 2023568475A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5
Authority
JP
Japan
Prior art keywords
aciminib
pharmaceutically acceptable
acceptable salt
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/054321 external-priority patent/WO2022238884A1/en
Publication of JP2024518426A publication Critical patent/JP2024518426A/ja
Publication of JP2024518426A5 publication Critical patent/JP2024518426A5/ja
Pending legal-status Critical Current

Links

JP2023568475A 2021-05-11 2022-05-10 投与レジメン Pending JP2024518426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (2)

Publication Number Publication Date
JP2024518426A JP2024518426A (ja) 2024-05-01
JP2024518426A5 true JP2024518426A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568475A Pending JP2024518426A (ja) 2021-05-11 2022-05-10 投与レジメン

Country Status (8)

Country Link
US (1) US20240245666A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337205A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518426A (cg-RX-API-DMAC7.html)
KR (1) KR20240006600A (cg-RX-API-DMAC7.html)
CN (1) CN117396202A (cg-RX-API-DMAC7.html)
CA (1) CA3218550A1 (cg-RX-API-DMAC7.html)
IL (1) IL308095A (cg-RX-API-DMAC7.html)
WO (1) WO2022238884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2670601T3 (es) * 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
CN112110880B (zh) * 2020-09-29 2022-09-09 天津红日药业股份有限公司 雄甾烷衍生物及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2022545835A5 (cg-RX-API-DMAC7.html)
JP2024516363A5 (cg-RX-API-DMAC7.html)
JP2019517542A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
JP2024507810A5 (cg-RX-API-DMAC7.html)
JP2022550919A5 (cg-RX-API-DMAC7.html)
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
JP2021509395A5 (cg-RX-API-DMAC7.html)
JP2022502450A5 (cg-RX-API-DMAC7.html)
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2021522246A5 (cg-RX-API-DMAC7.html)
JP2004525143A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2025517509A5 (cg-RX-API-DMAC7.html)
TW202110448A (zh) Parp抑制劑聯合vegfr抑制劑用於治療卵巢癌或乳腺癌的用途
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2023548303A5 (cg-RX-API-DMAC7.html)
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2022524819A (ja) カプシド集合調節剤固体製剤